化合物R547 T6312
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
10 mg | 741713-40-6 | ¥2,310.00 | 询底价 |
1 mg | 741713-40-6 | ¥632.00 | 询底价 |
25 mg | 741713-40-6 | ¥3,920.00 | 询底价 |
5 mg | 741713-40-6 | ¥1,480.00 | 询底价 |
1 mL | 741713-40-6 | ¥1,730.00 | 询底价 |
500 mg | 741713-40-6 | ¥15,700.00 | 询底价 |
50 mg | 741713-40-6 | ¥5,590.00 | 询底价 |
2 mg | 741713-40-6 | ¥915.00 | 询底价 |
100 mg | 741713-40-6 | ¥7,830.00 | 询底价 |
Product Introduction
Bioactivity
英文名: R547
描述: R547 (Ro 4584820) 是一种口服有效,选择性, ATP 竞争性CDK 抑制剂,对 CDK1/cyclin B、 CDK2/cyclin E 和 CDK4/cyclin D1 作用的Ki 值分别为 2 nM、3 nM、1 nM。
体外活性: R547 identified as a diaminopyrimidine compound, which is a potent and selective ATP-competitive CDK inhibitor. R547 effectively inhibits CDK1/cyclinB, CDK2/cyclinE, and CDK4/cyclinD1(Ki=1-3 nM) and is inactive(Ki>5,000 nM) against a panel of >120 unrelated kinases. R547 effectively inhibits the proliferation of tumor cell lines independent of multidrug resistant status, histologic type, retinoblastoma protein, or p53 status, with IC50s <0.60 μM. R547 reduces phosphorylation of the cellular retinoblastoma protein at specific CDK phosphorylation sites at the same concentrations that induced cell cycle arrest, suggesting a potential pharmaco dynamics marker for clinical use. R547 inhibits the proliferation of tumor cell lines and is active in all 19 cell lines tested irrespective of tissue of origin, multidrug resistance (MDR), p53, or retinoblastoma status. [1] R547 possessing both 5-and 6-fluoro substitution culminated in an Inhibitor with low, single-digit nanomolar potency against the CDKs(Ki=0.001,0.003,and 0.001 μM for CDK1,CDK2, and CDK4,respectively) and excellent cellular potency (IC50=0.08 μM,HCT116 cell line). [2]
体内活性: R547 administered with oral and i.v. dosing in multiple established human tumor significantly inhibits tumor activity(P < 0.01). R547 administered orally at dose of 40 mg/kg daily in colon, lung, breast, prostate, and melanoma human tumor xenograft models shows significant TGI (79-99%). R547 is equally efficacious (TGI, 61-95%) when dosed with 40 mg/kg i.v. once weekly. These doses of R547 are not toxic and did not result in body weight loss. R547 does not show signs of overt toxicity during the course of the 3-week study and any gross pathology at necropsies done at the end of the studies. [1] R547 inhibits tumor growth up to 95% in the HCT116 human colorectal tumor xenograft model in nude mice . R547 causes significant TGI in all of the models tested when dosed orally and i.v. at or below the maximum tolerated dose. R547 inhibits phosphorylation of retinoblastoma protein in tumors at the efficacious exposures in tumor xenograft models, providing a pharmacodynamic biomarker for clinical use. R547 reported here suggests that this is a promising molecule for evaluation in the treatment of solid tumors. [2]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 56 mg/mL (126.9 mM)
关键字: Glycogen synthase kinase 3 | kinase | multiple | tumor | cyclin-dependent | Apoptosis | R 547 | Cyclin dependent kinase | GSK-3 | human | Inhibitor | Glycogen synthase kinase-3 | R547 | CDK | R-547 | inhibit
相关产品: Hexamethonium Bromide | ICCB-19 hydrochloride | ALK/ROS1 inhibitor 2e HCL | PDK4-IN-1 hydrochloride | Anticancer agent 81 | Sophoraflavanone G | RAD51 Inhibitor B02 | Diphenyl disulfide | Pyrazoloacridine | NSC 146109 hydrochloride
相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Clinical Compound Library | Anti-Ovarian Cancer Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library | Metabolism Compound Library
化合物R547 T6312信息由TargetMol中国为您提供,如您想了解更多关于化合物R547 T6312报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途